Key Takeaway: Century Therapeutics has reported its second quarter 2026 financial results, highlighting a successful pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy aimed at treating type 1 diabetes. The company is on track for an IND submission in the fourth quarter of 2026. Preclinical data presented at ADA 2026 indicated that CNTY-813 achieved durable glucose control in vivo.
Market Sentiment Analysis
POSITIVE FACTORS
Successful pre-IND meeting with the FDA for CNTY-813.
CNTY-813 shows potential as a functional cure for type 1 diabetes.
Durable glucose control demonstrated in preclinical data.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+339%
120-day peak, hindsight
Typical move
2.2%
average across 3 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
CNTY-101
Phase 1 · Systemic Lupus Erythematosus
Full Press Release Details
Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026 CNTY-813 preclinical data from oral presentation at ADA 2026 showed durable glucose control in vivo, immune
Frequently Asked Questions
What is CNTY-813?
CNTY-813 is an iPSC-derived islet replacement therapy aimed at type 1 diabetes.
What were the results of the pre-IND meeting?
The pre-IND meeting with the FDA for CNTY-813 was successfully completed.
When is the IND submission planned?
The IND submission for CNTY-813 is on track for the fourth quarter of 2026.
What did the ADA 2026 presentation show?
The ADA 2026 presentation showed that CNTY-813 achieved durable glucose control in vivo.